论文部分内容阅读
根据Pharmaprojects/Pipeline最新数据显示,截至2014年5月,全球在研药物(包括临床前项目、处于临床研究及注册阶段的项目,以及增加新适应证的已上市药物)数量为11 622个,与2013年同期的10 648个相比,同比增幅达9.2%。在中国,前瞻产业研究院发布的《2014-2018年中国医药行业深度调研与投资战略规划分析报告》数据显示,2014年“处于活跃研发状态”的在研药物数量较2013年增长较快:截至2014年5月,处于Ⅰ期、Ⅱ期和Ⅲ期临床阶段的药物数量分别为1 592个、2 030个和750个,同比增幅分别为7.1%、6.9%和8.1%,处于临床前研究阶段的药物数量为5671个,同比增幅达11.7%。
According to the latest data from Pharmaprojects / Pipeline, as of May 2014, the number of globally researched drugs (including pre-clinical programs, projects in the clinical research and registration phase and listed drugs with new indications) was 11,622, with Comparing the same period of 2013 to the 10 648, an increase of 9.2%. In China, according to the “2014-2018 Analysis Report on China's Pharmaceutical Industry in-depth Research and Investment Strategy Planning” issued by Prospect Industry Research Institute, the number of under-researched drugs in “Active R & D Status” in 2014 witnessed a rapid increase over 2013 : As of May 2014, the number of drugs in Phase I, Phase II and Phase III clinical trials were 1 592, 2 030 and 750, respectively, up 7.1%, 6.9% and 8.1% respectively from the previous year, The research phase of the number of drugs for the 5671, an increase of 11.7%.